Department of Pharmacology, Monash University, Clayton, Victoria, Australia.
Curr Hypertens Rep. 2013 Feb;15(1):25-30. doi: 10.1007/s11906-012-0321-4.
It is quite well established that activation of the AT(2) receptor (AT(2)R) provides a counter-regulatory role to AT(1)R overactivity, particularly during pathological conditions. Indeed, a potential therapeutic role for the AT(2)R is currently being promulgated with the introduction of novel AT(2)R ligands such as compound 21 (C21). In this brief review, we will focus on recent evidence to suggest that AT(2)R exhibits promising organ protection in the context of the heart, kidney and brain, with inflammation and gender influencing outcome. However, this field is not without controversy since the 'flagship' ligand C21 has also come under scrutiny, although it is safe to say there is much evidence to support a potentially important role of AT(2)R in a number of cardiovascular diseases. This report updates recent data in this field.
已有充分证据表明，血管紧张素 II 型受体（AT2R）的激活对血管紧张素 II 型受体（AT1R）的过度活性提供了一种代偿性作用，特别是在病理条件下。事实上，随着新型 AT2R 配体如化合物 21（C21）的引入，AT2R 的潜在治疗作用正在得到推广。在这篇简短的综述中，我们将重点介绍最近的证据，表明 AT2R 在心脏、肾脏和大脑中具有有希望的器官保护作用，炎症和性别影响结果。然而，由于“旗舰”配体 C21 也受到了审查，这个领域并非没有争议，尽管可以说有大量证据支持 AT2R 在许多心血管疾病中具有重要作用。本报告更新了该领域的最新数据。
